Registered title, quoted from ClinicalTrials.gov
GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma
An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Chinese PLA General Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07670260, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Histologically or cytologically confirmed primary refractory or relapsed/progressive large B-cell lymphoma.
Inclusion criterion 2
CD19-positive B-cell lymphoma confirmed by flow cytometry or immunohistochemistry.
Inclusion criterion 4
ECOG performance status of 0 to 2 or KPS score greater than 80.
Inclusion criterion 5
ALT and AST ≤ 2.5 × upper limit of normal.
Inclusion criterion 9
Total bilirubin ≤ 2.0 mg/dL, equivalent to 34.2 μmol/L.
Inclusion criterion 10
HIV/AIDS infection.
Exclusion criterion 3
Pregnant or breastfeeding women.
Exclusion criterion 1
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07670260, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age 18 years or older.
- Histologically or cytologically confirmed primary refractory or relapsed/progressive large B-cell lymphoma.
- Expected survival of more than 3 months.
- CD19-positive B-cell lymphoma confirmed by flow cytometry or immunohistochemistry.
- ECOG performance status of 0 to 2 or KPS score greater than 80.
- Adequate venous access for leukapheresis or peripheral blood collection, with no contraindication to blood cell separation.
- White blood cell count ≥ 1 × 10\^9/L and lymphocyte count ≥ 0.3 × 10\^9/L.
- INR < 1.7 or prothrombin time prolonged by less than 4 seconds above the normal value.
- ALT and AST ≤ 2.5 × upper limit of normal.
- Total bilirubin ≤ 2.0 mg/dL, equivalent to 34.2 μmol/L.
- Able to understand and voluntarily sign the written informed consent form.
Exclusion Criteria:
- Pregnant or breastfeeding women.
- Active hepatitis B virus or hepatitis C virus infection.
- HIV/AIDS infection.
- Any uncontrolled active infection.
- Systemic corticosteroid use within 2 weeks before signing informed consent, except inhaled corticosteroids.
- Active cardiac disease requiring treatment or poorly controlled hypertension.
- Unstable or active ulcer disease or gastrointestinal bleeding.
- History of organ transplantation or currently awaiting organ transplantation.
- Central nervous system involvement by lymphoma.
- Current participation in another clinical trial.
- Any other condition that, in the investigator's judgment, makes the participant unsuitable for this clinical study.
Quoted from ClinicalTrials.gov, NCT07670260, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07670260, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.